Clinical Trial Update: Study of DS-8201a for Participants With Advanced Solid Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 study update for DS-8201a in participants with advanced solid malignant tumors has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasm Metastasis

Drugs mentioned

• DS-8201a (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Neoplasm Metastasis | Phase 1 | Status: COMPLETED | Results posted: 2021-06-14